Concomitant Administration of Mycobacterium bovis BCG with the Meningococcal C Conjugate Vaccine to Neonatal Mice Enhances Antibody Response and Protective Efficacy

Brynjólfsson, Siggeir F.; Bjarnarson, Stefania P.; Mori, Elena; Giudice, Giuseppe Del; Jónsdóttir, Ingileif

doi:10.1128/cvi.05247-11

Cited by 12 publications

(15 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At both age extremes, Th1 responses and sufficient cytotoxicity of lymphocytes have to be improved, e.g. by use of adjuvants [42,44,45,46], by concomitant vaccination with other vaccines [22], by change in antigen concentrations, e.g. high-dose vaccines for influenza [40] or zoster [39] in the elderly, or implementation of other dose intervals [15,20].…”

Section: Discussionmentioning

confidence: 99%

“…In mice, protective SBA levels were produced by neonatal administration of a meningococcal serogroup C conjugate vaccine using CRM 197 , encouraging neonatal immunization strategies in humans [22]. Interestingly, concomitant administration of BCG enhances the antibody response to meningococcal serogroup C conjugate vaccine in neonatal mice, probably by promoting Th1 responses [22]. …”

Section: Response To Vaccinations In Neonates and In The Aged Populationmentioning

confidence: 99%

See 1 more Smart Citation

Differential Approaches for Vaccination from Childhood to Old Age

Prelog¹

2012

Gerontology

View full text Add to dashboard Cite

Primary prevention strategies, such as vaccinations at the age extremes, in neonates and elderly individuals, demonstrate a challenge to health professionals and public health specialists. The aspects of the differentiation and maturation of the adaptive immune system, the functional implications of immunological immaturity or immunosenescence and its impact on vaccine immunogenicity and efficacy will be highlighted in this review. Several approaches have been undertaken to promote Th1 responses in neonates and to enhance immune functions in elderly, such as conjugation to carrier proteins, addition of adjuvants, concomitant vaccination with other vaccines, change in antigen concentrations or dose intervals or use of different administration routes. Also, early protection by maternal vaccination seems to be beneficial in neonates. However, it also appears necessary to think of other end points than antibody concentrations to assess vaccine efficacy in neonates or elderly, as also the cellular immune response may be impaired by the mechanisms of immaturity, underlying health conditions, immunosuppressive treatments or immunosenescence. Thus, lifespan vaccine programs should be implemented to all individuals on a population level not only to improve herd protection and to maintain protective antibody levels and immune memory, but also to cover all age groups, to protect unvaccinated elderly persons and to provide indirect protection for neonates and small infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Response To Vaccinations In Neonates and In The Aged Populationmentioning

confidence: 99%

Differential Approaches for Vaccination from Childhood to Old Age

Prelog¹

2012

Gerontology

View full text Add to dashboard Cite

show abstract

“…This dose of BCG has been commonly used by several authors working with mice [22][23][24] . It has been reported that BCG establishes itself in the spleen of mice over 15-20 days [25][26][27] .…”

Section: Jev Infection and Inoculation Of Mice With Bcgmentioning

confidence: 99%

“…In order to assess any neuromodulatory effect of BCG inoculation on JEV infection, we first inoculated suckling mice with BCG (10 6 CFU) [22][23][24] or vehicle. After 15 days (corresponding to the time reported for BCG to establish itself in mice [25][26][27] ), we challenged the mice with a virulent strain of 100 LD 50 JEV or PBS as per the schematic shown in Figure 1 .…”

Section: Bcg Delays the Onset Of Clinical Symptoms Post-jev Infectionmentioning

confidence: 99%

Bacillus Calmette-Guérin Confers Neuroprotection in a Murine Model of Japanese Encephalitis

Kulkarni

Mukherjee²,

Pandey³

et al. 2016

Neuroimmunomodulation

View full text Add to dashboard Cite

Objective: Japanese encephalitis (JE) is a debilitating disease caused by infection with the JE virus (JEV; family: Flaviviridae), which leaves neurological sequelae in survivors but more often leads to mortality. Neurodegeneration caused by inflammation is the primary pathology behind the clinical manifestation of encephalitis caused by JEV. Bacillus Calmette-Guérin (BCG) has been used in immunoprophylaxis for tuberculosis and in the adjuvant therapy of many malignancies, and has exhibited neuroprotective activities in experimental models of Parkinson and Alzheimer disease. This study aimed at assessing the neuroprotective role of BCG in a murine model of JE. Methods: Suckling mice were inoculated with 10⁶ CFU of BCG and at 18 days postinoculation were challenged with 100 LD₅₀ of JEV. PBS-inoculated mice were used as controls. Mice were sacrificed on days 2, 4, 6, and 8. Brain tissue was homogenized for RNA extraction. One-step real-time RT-PCR was performed to assess the relative gene expressions of TNF-α, IL-6, and iNOS. Results: The BCG-inoculated (BCG+JEV) group exhibited a significant delay in the presentation of neuropathological symptoms, longer survival, and a downregulation in the expression of TNF-α, IL-6, and iNOS on days 2, 4, and 6 post-JEV challenge compared to the JEV group. Conclusion: These findings indicate that the administration of BCG offers neuroprotection in the murine model of JE. BCG should therefore be further investigated as an adjuvant in the management of JE. BCG is an accepted vaccine for tuberculosis in many countries that are endemic for JEV. This approach may have a significant impact on the public health burden in these countries.

show abstract

“…Além disso, foi observado um aumento na atividade bactericida do soro dos animais que receberam as duas vacinas. (Brynjolfsson, Bjarnarson, 2011). Em outro estudo, a administração de BCG em combinação a uma vacina inativada contra Leishmania (KLV), em camundongos BALB/c, diminuiu tanto o tamanho das lesões da pele como a média do número de amastigotos encontrados nos macrófagos, com relação às lesões e a proliferação de amastigotos observada nos animais tratados com KLV ou BCG.…”

Section: Introductionunclassified

Desenvolvimento de vacinas proteicas contra Streptococcus pneumoniae: caracterização dos componetes adjuvantes da vacina celular pertussis e análise de novas combinações vacinais.

Rivillas¹

View full text Add to dashboard Cite

Concomitant Administration of Mycobacterium bovis BCG with the Meningococcal C Conjugate Vaccine to Neonatal Mice Enhances Antibody Response and Protective Efficacy

Cited by 12 publications

References 67 publications

Differential Approaches for Vaccination from Childhood to Old Age

Differential Approaches for Vaccination from Childhood to Old Age

Bacillus Calmette-Guérin Confers Neuroprotection in a Murine Model of Japanese Encephalitis

Desenvolvimento de vacinas proteicas contra Streptococcus pneumoniae: caracterização dos componetes adjuvantes da vacina celular pertussis e análise de novas combinações vacinais.

Contact Info

Product

Resources

About